SCHEDULE: RA Capital Amends VOR Bio Stake, Board Changes

RA Capital Management updated its beneficial ownership in VOR Biopharma to 29.0% following a 1-for-20 reverse stock split and announced a new board appointment.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, and Rajeev Shah collectively beneficially own 1,988,657 shares of VOR Biopharma Inc. common stock, representing 29.0% of the class.
• RA Capital Healthcare Fund, L.P. beneficially owns 1,891,035 shares, representing 27.6% of the class.
• The reported ownership percentages reflect an increase in the number of outstanding shares and a 1-for-20 reverse stock split of VOR Biopharma's common stock, effective September 18, 2025.
• Holdings include direct shares, common stock warrants for up to 1,056,072 shares, pre-funded warrants for up to 10,000,000 shares, and stock options.
• Warrants contain "Beneficial Ownership Blockers" preventing exercise if it leads to ownership exceeding 9.99% of outstanding common stock.
• Joshua Resnick resigned from the Board of Directors on August 25, 2025.
• Sarah Reed, General Counsel of RA Capital, was appointed to the Board of Directors on August 27, 2025.

Sentiment

Score: 6

Explanation: The filing indicates continued significant institutional investor interest and board representation, which is generally positive. However, the beneficial ownership blockers on warrants and the context of a reverse stock split (though not explicitly a negative in the filing) temper the overall sentiment.

Positives

• The appointment of Sarah Reed, General Counsel of RA Capital, to the Board of Directors may signal increased strategic alignment and oversight from a significant institutional investor.
• The exercisability of Pre-Funded Warrants at any time following the reverse stock split provides flexibility for RA Capital, although subject to beneficial ownership blockers.

Negatives

• The "Beneficial Ownership Blockers" prevent RA Capital Healthcare Fund, L.P. from fully exercising its warrants (up to 10,000,000 pre-funded warrants and 1,056,072 common stock warrants) if it would result in ownership exceeding 9.99% of the common stock outstanding, limiting immediate upside from these instruments.

Risks

• The inability to fully exercise warrants due to beneficial ownership blockers could limit RA Capital's ability to increase its stake or influence, potentially impacting future capital deployment or strategic moves.

Future Outlook

The filing indicates that Pre-Funded Warrants became exercisable at any time following the reverse stock split, subject to beneficial ownership limitations, suggesting potential for future capital deployment or increased stake by RA Capital.

Industry Context

This filing reflects an institutional investor's updated stake and board representation in a biopharma company. Such active involvement from a specialized healthcare fund like RA Capital often signals continued confidence in the company's long-term prospects or a desire for increased strategic influence, which is a common trend in the biotech sector where significant capital is often required for R&D and commercialization.

Comparison to Industry Standards

• NA

Management Changes

Stakeholder Impact

• Shareholders: The reverse stock split impacts the number of shares held and potentially the per-share price. The continued significant stake and board representation by RA Capital may provide confidence in institutional oversight.
• Management/Board: The resignation of Joshua Resnick and appointment of Sarah Reed changes the composition of the Board of Directors, potentially influencing strategic direction.

Next Steps

• Continued vesting of Sarah Reed's stock options on a monthly basis.
• Potential future exercise of warrants by RA Capital, subject to beneficial ownership blockers.

Key Dates

Recommendation

The filing primarily details an update to a significant institutional investor's stake and board representation following a reverse stock split. While RA Capital's continued high ownership and board presence suggest ongoing interest, the reverse stock split often indicates past underperformance. The beneficial ownership blockers on warrants limit immediate upside from those instruments. Without further operational or financial updates from VOR Biopharma, a 'hold' recommendation is prudent, awaiting more comprehensive company performance data.

Keywords

VOR Biopharma, RA Capital Management, Schedule 13D/A, Beneficial Ownership, Reverse Stock Split, Board of Directors, Warrants, Biopharma Investment, Institutional Investor